The Pediatric CNS Immunotherapy Signal That Sponsors Are Underreading
ReMIND's multi-antigen T cell data in 25 pediatric CNS patients points to a regulatory inflection point sponsors haven't mapped...
Pediatric Oncology
Pediatric Oncology Keeps Getting Treated as an Afterthought. The Biology Disagrees.
Children with cancer wait 6.5 years longer than adults to access new drugs. Adaptive and tumor-agnostic designs can close...
DIPG’s Biomarker Reckoning: What BIOMEDE Tells Us About Precision Oncology Trial Design When the Primary Endpoint Fails
BIOMEDE screened 279 DIPG patients across 45 centers using biopsy-driven tumor profiling — and its biomarker signals outlasted its...
BIOMEDE Missed Its Primary Endpoint — And Still Changed Pediatric CNS Trial Design Forever
The BIOMEDE Phase 2 trial in DIPG missed OS superiority but exposed a biomarker-survival link that should rewrite how...
Ewing Sarcoma’s EWS::FLI1 Trial Just Showed What Precision Oncology Has Been Promising for a Decade
A Nature Medicine phase 1/2 trial of trabectedin plus low-dose irinotecan targeting EWS::FLI1 in Ewing sarcoma signals a new...